ÂÜÀòÂÒÂ×

Naveed Siddiqi is a seasoned professional in the life sciences investment sector, serving as a Board Member at Asceneuron SA and Alentis Therapeutics since 2023, and a Senior Partner at Novo Holdings since 2019, where Naveed is also part of the Ventures Investment leadership team and the Investment Committee for Novo Holdings Asia PTE. Naveed has held key positions in various companies, including as an LP Advisory Committee Member at BGV and Board Member roles at F2G, Amolyt Pharma, and multiple others. Prior to current roles, Naveed was a Partner at Andera Partners, contributing significantly to investments in therapeutic and medical technology companies. Educational credentials include a Diploma in Company Direction from the Institute of Directors, an ACA from ICAEW, and an MBBS from Guy's Hospital Medical School.